Lv3
392 积分 2022-09-14 加入
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial
11天前
已完结
Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer
11天前
已完结
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial
12天前
已完结
Immune Checkpoint Inhibitors Plus Anlotinib Versus Anlotinib Alone as Third-Line Treatment in Advanced Non-Small-Cell Lung Cancer: A Retrospective Study
16天前
已关闭
First-line pyrotinib in advanced HER2-mutant non-small-cell lung cancer: a patient-centric phase 2 trial
23天前
已完结
Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
24天前
已完结
Efficacy and safety of antibody drug conjugate therapy in patients with human epidermal growth factor receptor 2‑positive non‑small cell lung cancer: A single‑arm systematic review and meta‑analysis
1个月前
已完结
Anlotinib optimizes anti-tumor innate immunity to potentiate the therapeutic effect of PD-1 blockade in lung cancer
1个月前
已完结
Cancer immunotherapies transition endothelial cells into HEVs that generate TCF1+ T lymphocyte niches through a feed-forward loop
1个月前
已完结
Anlotinib reduces the suppressive capacity of monocytic myeloid-derived suppressor cells and potentiates the immune microenvironment normalization window in a mouse lung cancer model
1个月前
已完结
皖公网安备34019202002308
